Workflow
Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Core Insights - Journey Medical Corporation reported total revenues of $15.0 million for the second quarter of 2025, showing a slight increase from $14.9 million in the same quarter of the previous year [5] - Emrosi™ generated net sales of $2.8 million in its first full quarter on the market, indicating strong initial adoption and prescription ramp [2][5] - The company joined the Russell 2000® and Russell 3000® Indexes in June 2025, reflecting its growth and market presence [2][11] Financial Results - Total net product revenues for the second quarter of 2025 were $15.0 million, compared to $14.9 million in the prior year quarter [5] - Gross margin increased to 67% in Q2 2025 from 61% in Q2 2024, attributed to lower product costs and a favorable sales mix [5] - Selling, general and administrative expenses rose to $11.9 million in Q2 2025, up from $10.3 million in Q2 2024, primarily due to costs associated with the Emrosi launch [5] - The net loss for the second quarter was $3.8 million, or $(0.16) per share, compared to a net loss of $3.4 million, or $(0.17) per share, in the prior year [5][16] - At the end of Q2 2025, the company had $20.3 million in cash and cash equivalents, unchanged from December 31, 2024 [5] Recent Corporate Highlights - In July 2025, Journey Medical expanded payer access for Emrosi to over 100 million commercial lives in the U.S., up from 54 million in May 2025 [4] - The full commercial launch of Emrosi began on April 7, 2025, and has shown strong traction in the market [4] - Emrosi was featured in a segment on "The Balancing Act®" on Lifetime TV, highlighting treatment options for managing rosacea [11]